Cabozantinib may help delay the need for chemotherapy in advanced patients.
News & Analysis: Exelixis
These businesses have proved they can stand the test of time.
These three companies are innovators in the development of cancer drugs, and they can also make you a lot of money.
This pharma stock can look forward to a year with more readouts, potential approvals, and new clinical assets providing value in the oncology space.
Consider these businesses the perfect blend of growth and value for your portfolio.
Bargains abound for patient long-term investors.
Start the year off right by investing in these top-tier companies.
These promising stocks have been flying under the radar this year, but they're worth another look.
These three names could soar early in 2020.
These are businesses with great growth potential that are trading at significant discounts.